Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 20 versus BRIELLYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 20 versus BRIELLYN.
BLISOVI FE 1/20 vs BRIELLYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
None Documented
None Documented
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Category C
Category C
Oral Contraceptive
Oral Contraceptive